Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a consent form and follow all study requirements for the full duration of the trial
- You are 18 years of age or older
- You have been diagnosed with acute myeloid leukemia (a type of blood cancer) that has been confirmed by a tissue sample, and it has come back or stopped responding to at least one previous treatment
- You have had a bone marrow test within 28 days before screening, or you may be able to skip this if enough cancer cells are already visible in your blood (confirm with trial site)
- If you received a previous experimental treatment, it must have been at least 2 weeks before joining, and any side effects must have mostly cleared up (except hair loss)
- You are well enough to carry out some daily activities — not completely bedridden (confirm with trial site)
- Your doctor expects you to live for at least 4 weeks
- You are able to swallow and take medication by mouth
- Your kidneys are working well enough to meet the trial's requirements (confirm with trial site)
- Your liver function is within an acceptable range (confirm with trial site)
- If you are a woman who could become pregnant, you must have a negative pregnancy test
Who may not be able to join:
- You have a specific subtype of leukemia called acute promyelocytic leukemia
- You are currently receiving chemotherapy (except for a drug called hydroxyurea; certain spinal-delivered drugs are allowed)
- Joining the trial would cause your total lifetime dose of a specific heart-related chemotherapy drug (daunorubicin) to exceed safe limits, especially if you have previously had radiation to your chest area
- There are signs that the leukemia has spread to your brain or spinal fluid and is currently active
- You are currently receiving certain growth-stimulating drugs (except erythropoietin, which helps with red blood cells)
- You have another active cancer, with some exceptions such as certain skin cancers, early-stage cervical changes, or a low-risk form of prostate cancer that has been removed (confirm with trial site)
- You have unstable heart disease or an uncontrolled irregular heartbeat
- You have another serious illness that your doctor believes would make intensive treatment unsafe for you
- You are currently pregnant or breastfeeding
- You have a known allergy to any ingredient in the study treatment
- Any other condition that could put you at extra risk or prevent you from completing the study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gina Keiffer, MD, Thomas Jefferson University
Phone: 215-955-2929
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of grade >= 3 non-hematologic dose limiting toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.